Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Novan Inc (NOVN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 60,934
  • Shares Outstanding, K 26,040
  • Annual Sales, $ 2,140 K
  • Annual Income, $ -37,130 K
  • 36-Month Beta 1.25
  • Price/Sales 30.48
  • Price/Cash Flow N/A
  • Price/Book 14.99

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/18
See More
  • Average Estimate -0.30
  • Number of Estimates 1
  • High Estimate -0.30
  • Low Estimate -0.30
  • Prior Year -0.47
  • Growth Rate Est. (year over year) +36.17%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.30 +0.43%
on 10/11/18
3.24 -28.70%
on 10/02/18
-0.39 (-14.44%)
since 09/21/18
3-Month
2.27 +1.76%
on 08/22/18
3.24 -28.70%
on 10/02/18
-0.39 (-14.44%)
since 07/23/18
52-Week
2.27 +1.76%
on 08/22/18
6.69 -65.47%
on 11/06/17
-3.05 (-56.90%)
since 10/23/17

Most Recent Stories

More News
Novan Extends Technical Production Capacity and Reaches Agreement with Orion Corporation

-- Extension of capacity complements existing internal operations, proprietary technological knowledge, intellectual property strategy and production skills

NOVN : 2.37 (+1.28%)
Is WisdomTree International High Dividend Fund (DTH) a Hot ETF Right Now?

Smart Beta ETF report for DTH

EFA : 62.09 (-2.16%)
IEFA : 58.39 (-2.18%)
DTH : 39.20 (-1.53%)
NOVN : 2.37 (+1.28%)
Novan's Phase 2 Molluscum Contagiosum Trial Fully Enrolled: Top Line Results Targeted in November

-- Trial enrollment completed meaningfully ahead of schedule

NOVN : 2.37 (+1.28%)
Novan Sees Hammer Chart Pattern: Time to Buy?

Novan has been struggling lately, but the selling pressure may be coming to an end soon.

NOVN : 2.37 (+1.28%)
Novan Receives FDA Guidance for SB204 and Acne Indication

-- Moderate-to-severe patient pathway re-affirmed

NOVN : 2.37 (+1.28%)
Is WisdomTree International LargeCap Dividend Fund (DOL) a Hot ETF Right Now?

Smart Beta ETF report for DOL

DOL : 44.82 (-1.90%)
NOVN : 2.37 (+1.28%)
Novan Announces Promising Clinical Results with SB414

-- In the recently completed Phase 1b trial for atopic dermatitis, clinical efficacy measures were highly correlated with critical and disease-relevant biomarker changes suggesting a topical nitric oxide...

NOVN : 2.37 (+1.28%)
Is WisdomTree International High Dividend Fund (DTH) a Hot ETF Right Now?

Smart Beta ETF report for DTH

EFA : 62.09 (-2.16%)
IEFA : 58.39 (-2.18%)
DTH : 39.20 (-1.53%)
NOVN : 2.37 (+1.28%)
Novan Provides Business Update via 10-Q, Adopts Incentive Plan and Agrees to CEO Contract

-- Company provides a comprehensive business update via its second quarter 2018 Form 10-Q filing

NOVN : 2.37 (+1.28%)
SB208 Increases Daily Nail Growth Rate over Four Weeks of Treatment

Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN) today announced that data from the Company's onychomycosis development program with SB208 gel demonstrated an enhanced nail growth rate in adult females...

NOVN : 2.37 (+1.28%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Trade NOVN with:

Business Summary

Novan, Inc. is a pharmaceutical company. It engaged in the development and commercialization of therapies using its nitric oxide platform for dermatology. The Company's product candidates primarily include SB204, SB206, SB208 and SB414 which are in pre-clinical trial stage. It develops product through...

See More

Key Turning Points

2nd Resistance Point 2.61
1st Resistance Point 2.48
Last Price 2.37
1st Support Level 2.27
2nd Support Level 2.19

See More

52-Week High 6.69
Fibonacci 61.8% 5.00
Fibonacci 50% 4.48
Fibonacci 38.2% 3.96
Last Price 2.37
52-Week Low 2.27

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar